International Journal of Pharma and Bio Sciences
 
 
    ISSN 0975-6299
www.ijpbs.net


REVIEW ARTICLE
Int J Pharm Bio Sci Volume 12 Issue 2, 2021 (April-June), Pages:42-49

A Review on Host Genetic Susceptibility to SARS CoV-2 Related Pneumonia

Shubham Dutta, Yatish Ravindra Thakare, Avinash Kshirsagar and Diptendu Sarkar
DOI: http://dx.doi.org/10.22376/ijpbs.2021.12.2.b42-49
Abstract:

The pandemic of coronavirus started in December 2019 is a great challenge for mankind. Even though the mortality rate is less but still the virus has successively managed to cause this catastrophe.  Many theories of the virus emergence have come forward but still the exact origin of the virus is unknown. This disease possesses serious concern as the appearance of the symptoms is different; mild to severe ARDS (Acute respiratory distress syndrome), also the strain circulating in different areas are showing different severity. It is very important to understand the host-pathogen interaction for the complete understanding of the disease. Along with the environmental factors, host genetic factors also play to accomplish disease severity. The main aim of this review is to understand various factors such as host immune response, host genes, age and factors which can change the pathogenesis of the virus from individual to individual. It might be able to address several ways to tackle the virus in different individuals.

Keywords: ARDS (Acute respiratory distress syndrome), host-pathogen interaction, genetic factors, respiratory disease, pathogenesis of virus
Full HTML:

REFERENCES

1.       Zúñiga J, Buendía-Roldán I, Zhao Y, Jiménez L, Torres D, Romo J, Ramírez G, Cruz A, Vargas-Alarcon G, Sheu CC, Chen F, Su L, Tager AM, Pardo A, Selman M, Christiani DC. Genetic variants associated with severe pneumonia in A/H1N1 influenza infection. Eur Respir J. 2012;39(3):604-10. doi: 10.1183/09031936.00020611, PMID 21737555.

2.       Gralinski LE, Ferris MT, Aylor DL, et al. Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross. PLOS Genet. 2015;11(10):e1005504. Published. doi: 10.1371/journal.pgen.1005504, PMID 26452100.

3.       Jiang RD, Liu MQ, Chen Y, Shan C, Zhou YW, Shen XR, Li Q, Zhang L, Zhu Y, Si HR, Wang Q, Min J, Wang X, Zhang W, Li B, Zhang HJ, Baric RS, Zhou P, Yang XL, Shi ZL. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting Enzyme 2. Cell. 2020;182(1):50-58.e8. doi: 10.1016/j.cell.2020.05.027, PMID 32516571.

4.       Tanigawa Y, Rivas M. Initial review and analysis of COVID-19. Host Genet Assoc Phenotypes Prepr. 2020. doi: 10.20944/preprints202003.0356.v1, PMID 2020030356.

5.       Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi: 10.1002/path.1570, PMID 15141377.

6.       WHO. Coronavirus disease (COVID-19) dashboard. Available from: https://covid19.who.int/.

7.       Bhuiyan MU, Blyth CC, West R, Lang J, Rahman T, Granland C, de Gier C, Borland ML, Thornton RB, Kirkham LS, Martin A, Richmond PC, Smith DW, Jaffe A, Snelling TL. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. BMC Pulm Med. 2019;19(1):71. doi: 10.1186/s12890-019-0835-5, PMID 30940126.

8.       Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis. 2020;96:131-5. doi: 10.1016/j.ijid.2020.04.086, PMID 32376308.

9.       Yoon SH, Lee KH, Kim JY, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Korean J Radiol. 2020;21(4):494-500. doi: 10.3348/kjr.2020.0132, pmid 32100485CrossRefPubMedGoogle Scholar.

10.     Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology perspective of coronavirus Disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. AJR Am J Roentgenol. 2020;214(5):1078-82. doi: 10.2214/AJR.20.22969, pmid 32108495CrossRefPubMedGoogle Scholar.

11.     Wong HYF, Lam HYS, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in covid-19 positive patients. Radiology. 2020;296(2):E72-8. doi: 10.1148/radiol.2020201160, pmid 32216717CrossRefPubMedGoogle Scholar.

12.     Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091, pmid 32217556 [abstract]/FREE Full TextGoogle Scholar.

13.     Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3, pmid 32171076CrossRefPubMedGoogle Scholar.

14.     Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J. 2001;18(1):196-208. doi: 10.1183/09031936.01.00213501, pmid 11510793 [abstract]/FREE Full TextGoogle Scholar.

15.     Henry TS, Kligerman SJ, Raptis CA, Mann H, Sechrist JW, Kanne JP. Imaging findings of vaping-associated lung injury. AJR Am J Roentgenol. 2020;214(3):498-505. doi: 10.2214/AJR.19.22251, pmid 31593518CrossRefPubMedGoogle Scholar.

16.     Best BMJ. Practice. Coronavirus Dis. 2019 (COVID-19) Epidemiology;2020.

17.     National institute for Health and Care Excellence. Coronavirus-COVID 19. Scenario: suspected coronavirus infection; 2020. Available from: https://cks.nice.org.uk/coronavirus-covid-19#!scenario.

18.     Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. doi: 10.1016/j.thromres.2020.04.013, PMID 32291094.

19.     Simpson S, Kay FU, Abbara S, et al. Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA - Secondary Publication. J Thorac Imaging. 2020;35(4):219-27. doi: 10.1097/RTI.0000000000000524, pmid 32324653CrossRefPubMedGoogle Scholar.

20.     Albarello F, Pianura E, Di Stefano F, Cristofaro M, Petrone A, Marchioni L, Palazzolo C, Schininà V, Nicastri E, Petrosillo N, Campioni P, Eskild P, Zumla A, Ippolito G, COVID 19 INMI Study Group. 2019-novel coronavirus severe adult respiratory distress syndrome in two cases in Italy: an uncommon radiological presentation. Int J Infect Dis. 2020;93:192-7. doi: 10.1016/j.ijid.2020.02.043, pmid 32112966PubMedGoogle Scholar.

21.     British Thoracic Society. Guidance on respiratory follow-up of patients with a clinic-radiological diagnosis of covid-19 pneumonia; 2020. Available from: https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/resp-follow-up-guidance-post-covid-pneumonia/.

22.     Zhao J, Yang Y, Huang H et al. Relationship between the ABO Blood Group and the COVID-19 susceptibility. medRxiv preprint 2020. doi: 10.1101/2020.03.11.20031096.

23.     Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293-4. doi: 10.1016/S0140-6736(03)13973-6, PMID 12892961.

24.     Enserink M. SARS treatment: interferon shows promise in monkeys. Science. 2004;303(5662):1273-5. doi: 10.1126/science.303.5662.1273a, PMID 14988528.

25.     He J, Feng D, de Vlas SJ, Wang H, Fontanet A, Zhang P, Plancoulaine S, Tang F, Zhan L, Yang H, Wang T, Richardus JH, Habbema JD, Cao W. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. BMC Infect Dis. 2006;6:106. doi: 10.1186/1471-2334-6-106, PMID 16824203.

26.     Ortiz-Fernández L, Sawalha AH. Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Genes Immun. 2020;21(4):269-72. doi: 10.1038/s41435-020-0107-7, PMID 32759995.

27.     Xia X. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense. Mol Biol Evol. 2020;37(9):2699-705. doi: 10.1093/molbev/msaa094, PMID 32289821.

28.     Meagher JL, Takata M, Gonçalves-Carneiro D, Keane SC, Rebendenne A, Ong H, Orr VK, MacDonald MR, Stuckey JA, Bieniasz PD, Smith JL. Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences. Proc Natl Acad Sci U S A. 2019;116(48):24303-9. doi: 10.1073/pnas.1913232116, PMID 31719195.

29.     Sharma S, Patnaik SK, Taggart RT, Baysal BE. The double-domain cytidine deaminase APOBEC3Gisacellularsite-specificRNAediting enzyme [sci rep:2016. p. 6(1):39100].

30.     Keicho N, Itoyama S, Kashiwase K, Phi NC, Long HT, Ha LD, Ban VV, Hoa BK, Hang NT, Hijikata M, Sakurada S, Satake M, Tokunaga K, Sasazuki T, Quy T. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum Immunol. 2009;70(7):527-31. doi: 10.1016/j.humimm.2009.05.006, PMID 19445991.

31.     Wang SF, Chen KH, Chen M, Li WY, Chen YJ, Tsao CH, Yen MY, Huang JC, Chen YM. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol. 2011;24(5):421-6. doi: 10.1089/vim.2011.0024, PMID 21958371.

32.     Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020;395(10236):1544-5. doi: 10.1016/S0140-6736(20)31024-2, PMID 32380044.

33.     Honce R, Schultz-Cherry S. Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Front Immunol. 2019;10:1071. doi: 10.3389/fimmu.2019.01071, PMID 31134099.

34.     Blasi F, Aliberti S, Pappalettera M, Tarsia P. 100 years of respiratory medicine: pneumonia. Respir Med. 2007;101(5):875-81, ISSN 0954-6111. doi: 10.1016/j.rmed.2007.02.016, PMID 17379493.

35.     Salnikova LE, Smelaya TV, Vesnina IN, Golubev AM, Moroz VV. Genetic susceptibility to nosocomial pneumonia, acute respiratory distress syndrome and poor outcome in patients at risk of critical illness. Inflammation. 2014;37(2):295-305. doi: 10.1007/s10753-013-9740-x, PMID 24127120.

36.     Wunderink RG, Waterer GW. Genetics of community-acquired pneumonia. Semin Respir Crit Care Med. 2005 Dec (Vol. 26, No. 06, pp. 553-562). Copyright;26(6);333. doi: 10.1055/s-2005-925522, PMID 16388427 Seventh Avenue, New York:NY10001.

37.     Waterer GW, Wunderink RG. Genetic susceptibility to pneumonia. Clin Chest Med. 2005 Mar 1;26(1):29-38. doi: 10.1016/j.ccm.2004.10.002, PMID 15802163.

38.     Jonczyk MS, Simon M, Kumar S, Fernandes VE, Sylvius N, Mallon AM, Denny P, Andrew PW. Genetic factors regulating lung vasculature and immune cell functions associate with resistance to pneumococcal infection. PLOS ONE. 2014;9(3):e89831. doi: 10.1371/journal.pone.0089831, PMID 24594938.

39.     Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260. doi: 10.1136/bmj.e4260, PMID 22786934.

40.     Chapman SJ, Khor CC, Vannberg FO, Rautanen A, Walley A, Segal S, Moore CE, Davies RJ, Day NP, Peshu N, Crook DW, Berkley JA, Williams TN, Scott JA, Hill AV. Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study. Crit Care. 2010 Dec 1;14(6):R227. doi: 10.1186/cc9377, PMID 21171993.

41.     Awasthi S, Yadav KK, Pandey M, Mahdi AA, Awasthi N. Interleukin 1 receptor antagonist (IL1RA) gene polymorphism and levels associated with adverse outcome in severe community-acquired pneumonia in children: A hospital-based study in India. Pediatr Pulmonol. 2018;53(9):1276-83. doi: 10.1002/ppul.24090, PMID 29943912.

42.     Cai X, Fu Y, Chen Q. Association between TLR4 A299G polymorphism and pneumonia risk: A meta-analysis. Med Sci Monit. 2015;21:625-9. doi: 10.12659/MSM.892557, PMID 25720378.

43.     Chung LP, Waterer GW. Genetic predisposition to respiratory infection and sepsis. Crit Rev Clin Lab Sci. 2011;48(5-6):250-68. doi: 10.3109/10408363.2011.641517, PMID 22185617.

44.     Rahmel T, Rump K, Peters J, Adamzik M. Aquaporin 5-1364-A/C promoter polymorphism is associated with pulmonary inflammation and survival in acute respiratory distress syndrome. Anesthesiology. 2019;130(3):404-13. doi: 10.1097/ALN.0000000000002560, PMID 30689610.

45.     Shi X, Ma Y, Li H, Yu H. Association between FCGR2A rs1801274 and MUC5B rs35705950 variations and pneumonia susceptibility. BMC Med Genet. 2020;21(1):71. doi: 10.1186/s12881-020-01005-1, PMID 32252656.

46.     Song W, Tan H, Wang S, Zhang Y, Ding Y. Association of High Mobility Group Box Protein B1 Gene Polymorphisms. Association of High Mobility Group Box Protein B1 Gene Polymorphisms with Pneumonia Susceptibility and Severity. Genet Test Mol Biomarkers. 2019;23(1):3-11. doi: 10.1089/gtmb.2018.0174, PMID 30562142.

47.     Wan QQ, Li JL, Ye QF, Zhou JD. Genetic association of tumor necrosis factor-β, interleukin-10, and interleukin-1 gene cluster polymorphism with susceptibility to pneumonia in kidney transplant recipients. Transplant Proc. 2013;45(6):2211-4. doi: 10.1016/j.transproceed.2013.02.122, PMID 23953530.

48.     Wang X, Guo J, Wang Y, Xiao Y, Wang L, Hua S. Genetic variants of interferon regulatory factor 5 associated with the risk of community-acquired pneumonia. Gene. 2018;679:73-80. doi: 10.1016/j.gene.2018.08.080, PMID 30176312.

49.     Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am. 2004;18(4):743-59, vii, vii. doi: 10.1016/j.idc.2004.07.004, PMID 15555822.

50.     Wunderink RG, Waterer GW. Genetics of sepsis and pneumonia. Curr Opin Crit Care. 2003;9(5):384-9. doi: 10.1097/00075198-200310000-00008, PMID 14508151.

51.     Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi: 10.1038/s41586-020-2012-7, PMID 32015507.

52.     Qing E, Gallagher T. SARS coronavirus redux. Trends Immunol. 2020;41(4):271-3. doi: 10.1016/j.it.2020.02.007, PMID 32173256.

53.     Janko Nikolich-Zugich & Kenneth S. Knox & Carlos Tafich Rios & Bhupinder Natt & Deepta Bhattacharya & Mindy J. Fain. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes; (Gero. Science) 2020.

54.     McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346(6):429-37. doi: 10.1056/NEJMra011994, PMID 11832532.

55.     Bhuiyan MU, Snelling TL, West R, et al. Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: a case-control study protocol. BMJ Open. 2018;8(3):e020646. Published. doi: 10.1136/bmjopen-2017-020646, PMID 29549211.

56.     Khor CC, Hibberd ML. Hosts. Host-pathogen interactions revealed by human genome-wide surveys. Trends Genet. 2012;28(5):233-43. doi: 10.1016/j.tig.2012.02.001, PMID 22445588.

[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions